Watch HAE. Know when insiders buy.
One email the day a filing lands. Free.
HAE
HAEMONETICS CORP
106.24
+0.04 +0.04%
USD · close Sep 16
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
41
WATCH · shorts 41
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.8BP/E 51.3DIV YIELD —FCF YIELD 6.02%REV TTM $1.4B +0.4%NET INCOME $96.3M −41.1%NET DEBT $964.8M52W 47.67 – 108.80SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2027 · Jun 27 | $339.4M | +5.6% | 59.8% | $57.5M | $33M | −3.0% | 0.72 | $52.3M | $7.9M | $44.4M | Aug 6 |
| Q4 2026 · Mar 28derived | $346.4M | +4.8% | 57.2% | −$23M | −$20.1M | −134.7% | -0.41 | $70.9M | $17.7M | $53.3M | May 20 |
| Q3 2026 · Dec 27 | $339M | −2.7% | 59.7% | $67.4M | $44.7M | +19.3% | 0.95 | $93.6M | $6.3M | $87.2M | Feb 5 |
| Q2 2026 · Sep 27 | $327.3M | −5.3% | 59.5% | $58.5M | $38.7M | +14.3% | 0.81 | $111.3M | $5M | $106.3M | Feb 5 |
| Q1 2026 · Jun 28 | $321.4M | −4.4% | 59.8% | $53.9M | $34M | −11.3% | 0.70 | $17.4M | $3.8M | $13.6M | Aug 6 |
| Q4 2025 · Mar 29derived | $330.6M | −3.7% | 58.4% | $71.3M | $58M | +184.7% | 1.17 | $116.6M | $15.6M | $100.9M | May 20 |
| Q3 2025 · Dec 28 | $348.5M | +3.7% | 55.5% | $59M | $37.5M | +20.0% | 0.74 | $43.8M | $8.5M | $35.2M | Feb 5 |
| Q2 2025 · Sep 28 | $345.5M | +8.6% | 54.2% | $51.7M | $33.8M | +35.8% | 0.66 | $48.8M | $9.4M | $39.4M | Feb 5 |
| Q1 2025 · Jun 29 | $336.2M | — | 52.0% | $39.8M | $38.4M | — | 0.74 | −$27.4M | $5.7M | −$33.1M | Feb 5 |
| Q4 2024 · Mar 30derived | $343.3M | — | 51.2% | $29.9M | $20.4M | — | 0.40 | $64.1M | $6.7M | $57.4M | May 20 |
| Q3 2024 · Dec 30 | $336.3M | — | 52.9% | $46M | $31.2M | — | 0.61 | −$540K | $14.6M | −$15.2M | Feb 6 |
| Q2 2024 · Sep 30 | $318.2M | — | 53.6% | $35.3M | $24.9M | — | 0.48 | $99.1M | $9.1M | $90M | Feb 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Mar 28 | $1.3B | 59.0% | $156.7M | $97.3M | 7.3% | 2.05 | $293.2M | $32.8M | $260.4M | $175M | — |
| FY2025 · to Mar 29 | $1.4B | 55.0% | $221.8M | $167.7M | 12.3% | 3.31 | $181.7M | $39.3M | $142.4M | $225M | — |
| FY2024 · to Mar 30 | $1.3B | 52.8% | $164.9M | $117.6M | 9.0% | 2.29 | $181.8M | $38.1M | $143.6M | $0 | — |
| FY2023 · to Apr 1 | $1.2B | 52.6% | $156M | $115.4M | 9.9% | 2.24 | $273.1M | $191.3M | $81.7M | $75M | — |
| FY2022 · to Apr 2 | $993.2M | 50.9% | $80.8M | $43.4M | 4.4% | 0.84 | $172.3M | $96.5M | $75.8M | $0 | — |
| FY2021 · to Apr 3 | — | — | $89.7M | $79.5M | — | 1.55 | $108.8M | $37M | $71.8M | $0 | — |
Every number comes from HAEMONETICS CORP's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.